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Abstract
Background: Chronic pain, smoking, and opioid use, contribute to a significant economic
burden in the United States. Chronic pain affects all aspects of life, and is influenced by the use
of cigarettes and opioids alike. Researchers suggest that there is a higher use of cigarettes and
opioids in individuals with chronic pain. Chronic pain can promote smoking and smokers are
more likely to use opioids. With the evidence that patients who smoke a higher number of
cigarettes per day report higher pain, it is possible that smoking may be a stress-reducing
behavioral response related to pain. Moreover, higher frequency and intensity of pain, can
contribute to a higher dose of opioid therapy. Hence, it is critical to understand smoking
behaviors and opioid use in managing pain among those with chronic pain.
Purpose: The purpose of this project was to examine the relationship between smoking and
opioid use in managing pain among patients at a chronic pain management clinic.
Methods: This project was a single-center, retrospective chart review to evaluate the relationship
between smoking, chronic pain, and the use of opioids. The project was conducted over a sixmonth time frame (from June 1, 2017- November 30, 2017) and the sample consisted of 37
subjects: 7 smokers and 30 non-smokers. Information on smoking history, opioid medication
use, and perceived pain using the Global Pain Scale (GPS) was obtained from attendants at a
pain clinic. A two-sample t-test was used to compare differences in average pain scores and
morphine milligram equivalent (MME) for opioid use between smokers and non-smokers.
Results: The average pain rating for the entire project population (n=37) was six, with an
average GPS score of 31. The average acceptable pain level was five. When the data was
analyzed separately, smokers were found to have an average GPS score of 30 and an
average pain rating of 6.7/10, while non-smokers were found to have an average GPS of 21
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and an average pain score of 6/10; but these differences were not statistically significant.
The MME was higher for smokers than for non-smokers (26.4mg MME vs. 21.9mg MME), but
these differences were not statistically significant.
Conclusion: Patients with chronic pain who smoke have a higher pain rating compared to nonsmokers, therefore, possibly requiring higher use of opioids. Providers are encouraged to use
evidence-based smoking cessation treatment to assist their patients who smoke. To improve
overall patient health, patient experience, and quality of life, providers should screen, advise, and
counsel patients with chronic pain to abstain from smoking, which may ultimately result in
decreased opioid need and use.

Keywords: Smoking, chronic pain, opioids
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A Retrospective Analysis Evaluating the Relationship Between Tobacco use and Pain Perception
using the Global Pain Scale (GPS) in Opioid Dependent Adults
Background
Chronic pain and tobacco use are prevalent healthcare issues faced by primary care
providers. Tobacco use is the leading cause of preventable death in the United States,
resulting in an estimated 480,000 deaths and $19 billion spent on health care annually
(Nguyen, 2016). Similarly, chronic pain, when treated with opioids has been associated
with opioid misuse and contributes to the problem of opioid addiction (Gaskin & Richard,
2012). There is developing evidence that a relationship between cigarette smoking and
opioids exists. Young-Wolff et al., (2017) suggests the there is a higher use of cigarettes and
opioids in individuals with chronic pain. The purpose of this project was to examine the
relationship between smoking and prescribed opioids among patients with chronic pain..
Chronic pain has been found to coincide with increased smoking behavior (Zale et
al., 2016; Young-Wolff et al., 2017). Despite extensive research, little is known about this
relationship. Though nicotine and opioids share a similar addiction pathway within the
brain, how this manifests remains in question. However, it is clear that Kentucky ranks
higher than the national average in both tobacco and opioid use, therefore healthcare
providers must address both forms of addiction (Nguyen, 2016).
Addiction
Addiction is based on the principle of pleasure to the extent that it can alter the
structure and function of the brain (Volkow & Morales, 2015). The reward center of the brain
is the ventral tegmental area (VTA) located in the brainstem. The VTA is a dopamine-producing
area strongly associated with motivation and reward. Dopamine creates a pleasing and enjoyable
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sensation, hence, a dopamine producing action (ie smoking, gambling) can easily become
habitual (Sutherland et al., 2016). Over time, exposure to an addictive substance or behavior can
alter the brain chemistry, requiring more dopamine to achieve the same “high” effect.
Nicotine, the psychoactive substance in tobacco products, acts on acetylcholine receptors
and potentiates a release of dopamine in the brain (Abburi et al., 2017). This release of
dopamine can result in anti-nociceptive properties, thereby exhibiting an analgesic effect in
the body (Abburi et al., 2017; Goesling et al., 2015). In a similar fashion, chronic pain relief
from opioids can lead to abuse when it hijacks the reward circuitry of the brain, increasing
the reliance on opioids as a means to ameliorate pain. Addiction to opioids is characterized
by the inability to abstain from the substance. This increasing reliance on opioids leads to
dependence, a physiological need to take the drug, accompanied by tolerance, requiring a
higher dose to achieve the same effect. Without continual use of the substance, withdrawal
symptoms can occur. Opioid addiction can include physical dependence, but there is a
dysfunction in emotional response resulting in compulsive substance use despite harm
(Goesling et al., 2015).
Tobacco Use
Smoking is the leading cause of preventable death in the United States with an
economic health burden of $19 billion (Nguyen, 2016; USDHHS, 2014). In Kentucky,
twenty-six percent of adults use tobacco, ranking second in the nation for prevalence of
tobacco use, behind West Virginia at 26.9 percent (Odani et al., 2018). Tobacco use is an
addictive behavior causing damage to nearly every organ in the body. It contributes to many
health problems including respiratory and cardiovascular disease, stroke, and cancer (Odani
et al., 2018; USDHHS, 2014).
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Nicotine impairs blood flow and oxygenation to tissues at the cellular level.
Furthermore, nicotine has also been shown to accelerate intervertebral disc degeneration
resulting in higher instance of chronic back pain (Young-Wolff et al., 2017). Although the
nicotine in tobacco products may have some analgesic effect on pain, the other constituents of
tobacco products are known to have severe detrimental effects on most body systems, which can
result in chronic pain (USDHHS, 2014). Evidence suggests the link between pain and smoking
can be associated with more intense pain and pain interference (Goesling et al., 2015).
Tobacco Quit Strategies
Healthcare providers (HCP) have been strongly encouraged to address nicotine use at
every healthcare visit (Kruger et al., 2016). The 5 A’s is a behavioral counseling framework
used to engage patients in tobacco treatment (Laschober et al., 2015 & Aveyard et al., 2012). The
acronym helps guide HCPs to: ask patients about their tobacco use, advise them to quit, assess
willingness to quit, assist in quitting, and arrange for follow-up contact. Implementing this
technique may help guide providers to engage patients in tobacco cessation strategies.
Researchers also suggest that providers should take environmental, cognitive and behavioral
factors into account when developing a plan of care for patients who smoke (Laschober et al.,
2015). Using the 5 A’s as a brief intervention by a medical provider can increase quit attempts
for patients in diverse clinical settings (Kruger et al., 2016; Laschober et al., 2015).
There are seven FDA approved medications (Varenicline, Bupropion, nicotine patch,
nicotine gum, nicotine lozenge, and nicotine nasal spray) that have been shown to increase
the success of a smoking cessation attempt. When behavioral therapy is combined with
Nicotine Replacement Therapy (NRT), the success of smoking cessation is optimized (Fiore
et al, 2008). The guideline used by the CDC indicates that medication plus counseling by a
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healthcare provider increases the likelihood of tobacco abstinence by almost a third than if
one technique was used alone (Fiore et al., 2008). Brief interventions combined with the use
of smoking cessation medications can greatly improve tobacco cessation among patients in
primary care settings (Fiore et al., 2008; Aveyard et al., 2012).
Opioid use
Opioids have had a long history for management of both acute and chronic pain.
Unfortunately, opioids have been misused by those without chronic pain resulting in
addiction. In 2016, Kentucky reported 33.1 per 100,000 deaths related to the misuse of
opioids. This was significantly higher than the national average of 16.3 per 100,000 deaths
(Hedegaard, Warner & Minino, 2017). While morphine was the most common detectable
substance related to overdose fatalities, oxycodone accounted for 19 percent of deaths and
hydrocodone accounted for 16 percent of deaths by overdose (Hedegarrd et al., 2017).
Despite the association between opioids and addiction, there is a role for opioids in the
management of chronic pain. The current CDC guideline (Figure 10) recommends that HCPs
first engage in nonpharmacologic therapy as the preferred treatment for chronic pain (Dowell,
Haegerich, & Chou, 2016). Opioid treatment should be considered for those patients who have
chronic renal failure, cannot be prescribed NSAIDs, fibromyalgia, and certain types of arthritis.
The guideline recommends that clinicians prescribe immediate release opioids at the
lowest effective dosage. Morphine milligram equivalents (MME) are used to standardize the
dosage of various opioids as a constant measure. Caution must be used when increasing dosages
greater than 50 MME, as this puts the patient at higher risk for opioid misuse (Dowell et al.,
2016). Additionally, the CDC recommends that risk factors for opioid related harms are
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evaluated periodically, along with urine drug screens, and the use of the state’s opioid
monitoring system (Dowell et al., 2016).
Chronic Pain
Chronic pain is defined as pain lasting longer than six months and affects over 100
million Americans (IASP, 2017; Nahin, 2015). The International Association for the Study
of Pain (2017) recognizes it as a multidimensional sensation. Chronic pain affects
morbidity, sleep, cognition, mobility, psychosocial behaviors, and overall functional status.
The most common types of chronic pain seen in primary care include low back pain, headache
and pain caused by conditions such as fibromyalgia, multiple sclerosis and diabetes (Orhurhu,
Pittelkow, & Hooten, 2015). It is estimated that the United States spends $261-300 billion in
healthcare costs related to chronic pain (Gaskin, & Richard, 2012). The economic burdens of
managing chronic pain have a significant impact on healthcare costs in the United States.
The Global Pain Scale (GPS) is a tool used to quantify pain perception (Figure 1). There
are four areas addressed in this tool regarding the patient’s pain, feelings, clinical outcomes and
activities. A higher number reported on the GPS is associated with a higher instance, frequency
and intensity of pain. A composite score allows comparisons between visits to monitor the
patient’s progress and effectiveness of treatment (Gentile et al., 2011) This tool is easily
administered and can be completed by the patient. The GPS was found to have high criterion
validity and high construct validity in patients with chronic pain (Gentile et al., 2011).
The Kentucky All Schedule Prescription Electronic Reporting (KASPER) is an
electronic system used by pharmacists and clinicians to monitor opioid prescribing
(Blumenschein et al., 2010). Kentucky House Bill 1 (HB1), passed in 2012, was designed to
regulate the prescribing of controlled substances and prescription drug abuse in Kentucky
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(Freeman, Goodin, Troske, & Talbert, 2015). Kentucky HB1 requires all patients who are
prescribed a controlled substance in the state to abide by a ‘drug contract’ signed by both
the patient and the provider at the start of treatment. The agreement (Figure 3) adheres to
the conditions for continual prescribing and requires an annual urine drug test, in addition
to a clinical diagnosis, physical exam, behavioral screening, and a KASPER report at each
visit (Freeman et al., 2015).
Using the Health Belief Model (HBM) and its constructs, a practitioner can assess what
personal or environmental events prompt behavior change for the patient, thus, determining the
self-efficacy and likelihood for the patient to adhere to and maintain a health promotion practice
(Green & Murphy, 2014). The goal of the first construct of perceived severity helps the
patient to understand how tobacco use contributes to chronic pain and opioid use. Through
motivational interviewing, HCPs can help patients identify perceived facilitators and
barriers, contributing to smoking cessation in relation to chronic pain.
Individually, smoking behavior and opioids that are prescribed for chronic pain
management contribute to rising healthcare costs and patient mortality (Hooten et al., 2014).
Addressing these additive problems necessitate that HCPs assess how patients use these
drugs as well as their perception of the relationship of these two to each other. As these
addictive problems are particularly high in Kentucky, exploring the relationship between
them is of utmost importance.
Methods
Objectives/Specific aims
An urban primary care clinic developed a sub-clinic in response to the clinical
treatment guidelines developed by the American Pain Association (APA). The Chronic
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Opioid Analgesic Therapy (COAT) clinic was established for opioid surveillance. The
COAT clinic also met the APA guidelines and Kentucky House Bill 1 regarding opioid use.
Patients are seen once a month to assess and evaluate the effectiveness of their treatment.
The purpose of this project was to examine the relationship between smoking and chronic
pain management in patients at the COAT clinic.
The aims for this study included:
1. Examine the pain scores (using the GPS) of all patients managed in the COAT
clinic, including both smokers and non-smokers.
2. Examine the differences in pain level (current pain level, GPS scores, and
acceptable pain level) and opioid use (morphine equivalents) between smokers
and non-smokers.
Setting
This project took place within an urban primary care clinic in a southern city. The
COAT clinic was offered twice a month, had two primary providers, a physician and a
nurse practitioner, as well as a registered nurse to assist the patients. Appointments lasted
approximately 15 minutes and patients were given a 30-day supply of their medication via
written prescription.
Population
A total of 37 male and female subjects, all over the age of 18, were enrolled in the
COAT clinic. These patients had a clinically diagnosed reason for needing a controlled
substance, such as tramadol or hydrocodone, to help control their pain. Inclusion criteria
were: admittance into the COAT clinic between June 1, 2017- November 30, 2017, adults
over the age of 18, a clinically diagnosed pain condition, and adherence to the COAT clinic
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contract. Exclusion criteria were dismissal from the COAT clinic or failure to adhere to the
medication contract (for example, having a positive urine drug screen).
Data Collection
A retrospective chart review was conducted over a six-month time frame: June 1, 2017November 30, 2017. Approval from the University of Kentucky Institutional Review Board
(IRB) was obtained prior to the collection of data. The data was extracted from the electronic
health record and placed into a secure, web-based application. A crosswalk table was designed
with 37 patient records assigned to a study number so that no patient identifying information was
used during the data collection and analysis process. These study numbers replaced medical
record numbers on all electronic data collection forms and electronic data used in data collection
and data analysis as to protect patient privacy.
Measures
Data were collected via patient chart review. The following variables were included:
demographics, smoking status, comorbidities, and pain outcomes.
Demographic variables included age (years), gender (male vs. female), co-morbidities,
and diagnosis. Smoking status was based on documented self-reported current smoking (yes vs
no) at each clinic visit. Four co-morbidities were evaluated based on documented clinical
diagnosis: Hypertension, hyperlipidemia, diabetes mellitus (DM), and anxiety/depression. Pain
medications and amount prescribed in the COAT clinic (tramadol vs. hydrocodone vs.
oxycodone), pain level at the time of COAT clinic appointment (on a scale of 1-10), average
GPS score (1-100), and acceptable Pain Level (on a scale of 1-10).
The average scores on the GPS, pain level at the time of appointment and acceptable pain
level were determined based on scores obtained over six-time points. Opioid use was converted
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to oral morphine milligram equivalent (MME) doses according to the equianalgesic dose chart
used by the CDC (Table 4) (Dowell et al., 2016).
Data Analysis
Descriptive statistics, including means and standard deviations or frequency distributions,
were used to summarize study variables. The variables included age, gender, smoking status
(yes/no), acceptable pain level (1-10), pain level at the time of the COAT clinic appointment (110) and average GPS score (1-100) over the six-month time frame. Additional patient
characteristics were co-morbidities, pain-related diagnoses, prescribed opioid, and side effects.
Of the 37 patients who met the inclusion criteria for this project, only seven were
smokers. Data was analyzed for the entire group and then for a sub-group, comparing seven
smokers to a matched sample of seven non-smokers. Therefore, the emphasis of the analysis is
on descriptive statistics. MME were used as a constant to standardize the dosage of various
opioids. A two-sample t-test was used to compare differences in average pain scores and MME
for opioid use between smokers and non-smokers. Data analysis was conducted using SPSS,
version 24 with an alpha level of .05.
Results
Sample characteristics
A total of 37 patients were identified for this project, where 19% (n=7) were
identified as smokers and 81% (n=30) were non-smokers. The mean age was 62. Over half
of the population was female (76%) (Table 1). The average pain rating at the time of the
COAT clinic appointment for all participants (n=37) was six out of ten, with an average
GPS score of 31, and the average acceptable pain level was five out of ten (see Table 1).
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Clinical diagnoses included arthritis, generalized pain, Degenerative Disc Disease,
arthropathy, neuropathy, cervicalgia, and other diagnoses such as May Turner syndrome and
Charcot-Marie Syndrome (Figure 9). Arthritis was found to be the most common diagnosis for
smokers and non-smokers. The narcotics prescribed to the patients included Tramadol 50mg,
Hydrocodone 10mg, Hydrocodone 7.5mg, Hydrocodone 5mg, and Oxycodone 10mg. Side
effects of pain medications included asymptomatic, constipation, drowsiness, pruritus, increased
sweating, insomnia, sexual dysfunction, and fatigue. Smokers were found to have more side
effects than non-smokers in the sub-group (5 vs. 3). The charting reflected two of the seven
smokers were interested in smoking cessation.
In Figure 8, a list of co-morbidities is provided comparing the smokers and nonsmokers. Smokers were found to have higher instance of neuropathy (29% vs 7%) and
depression/anxiety (71% vs. 33%). There were no other differences in co-morbidities noted.
A comparison of pain location was also explored, with smokers reporting a higher level of
lower extremity pain than non-smokers (86% vs. 33%).
Smokers had higher levels of pain at the time of each appointment and higher GPS
scores compared to non-smokers (Table 2). There were no differences in acceptable pain
levels between smokers and non-smokers. In a similar fashion, the MME was higher for
smokers as compared to non-smokers (26.4 MME vs. 21.9 MME). The relationship was not
statistically significant (p=0.42).
Matched Control
A sub-group (n=7) was identified from the original non-smoking group (n=30) for
the purpose of a matched comparison. The same sample of smokers was used when
comparing these two sub-groups (Table 3). Both groups consisted of one male and six
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females and had an average age of 62. Arthritis was the prominent diagnosis for both groups
(nine out of fourteen).
The average MME for the smokers was 26.4 MME vs.19.6 MME for the nonsmoking sub-group. The smokers had an average GPS score of 34.2 and an acceptable pain
rating of five out of ten. The non-smoking sub-group had an average GPS of 27.3 and an
acceptable pain rating of six out of ten. Both groups reported a pain level of seven out of ten
at the time of their COAT appointments. There was no statistical difference in any of these
variables.
Discussion
Key Findings
Although the sample size was small, some of the project findings are of clinical
relevance. Primarily, there were two main outcomes between smokers and non-smokers on
chronic opioids, 1) smokers used higher doses of opioids and 2) there was a higher instance of
anxiety and depression among smokers. The relationship between pain, smoking, and opioids is
concerning and should be recognized for the potential interactions by HCPs.
The entire sample in this project mirrored demographics noted in the literature reviewed.
For example, women have been found to have higher occurrence of chronic pain for a variety of
reasons. Female hormones may increase pain sensitivity, and greater nerve density could result
in intense pain severity in women (Young-Wolff et al., 2017). Though not included in this
project, one might hypothesize that women seek healthcare more than men and therefore would
have a greater likelihood of being treated for chronic pain. Hirsh et al., (2014) found that gender
of both patients and providers can affect the management of chronic pain in patients.
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The mean age in this sample was 62 years. From the perspective of treating chronic pain,
this was not unexpected. In those under the age of 50 and under the age of 18, the use of chronic
opioids is not without significant concern. The current guidelines do not address the use of
opioids in the pediatric population, and concern of dependence and/or addiction has been
identified (Dowell et al., 2016). Older adults have more chronic conditions that worsen with age.
For example, arthritis is a common problem seen in older adults who are not always good
candidates for anti-inflammatories due to chronic renal or cardiovascular issues (Malec, &
Shega, 2015). Across this sample, arthritis was a primary diagnosis.
Although one-fourth of Kentuckians smoke tobacco (Odani et al., 2018), there was a low
percentage of smokers in the project sample. Due to the brain’s addiction pathway, concurrent
opioid and smoking can influence the pain response to opioids. Though the smoking sample size
in this project was small, smokers reported more pain and higher MME per day. The shared
acetylcholine receptors in the opioid and nicotine addiction pathways is a potential reason for
why smoking may hinder pain management (Sutherland et al., 2016).
The incidence of anxiety and depression as a co-morbid diagnosis among the patients in
this sample revealed disparity between smokers and non-smokers. Independently, smokers
without chronic pain have higher instances of anxiety and depression. Chronic pain is also
identified with anxiety and depression, irrespective of smoking status. Therefore, when the two
are combined it is not surprising to find that the smokers in this sample had a higher incidence of
anxiety and depression as a comorbidity. This is supported by Ditre et al. (2015), who reported
that smokers have higher anxiety in relation to chronic pain. What remains unclear is the
direction of the relationship. It is possible that depression could occur as a result of chronic pain
in patients with pain-smoking relations or vice versa.
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Limitations
Several limitations were identified in the design and procedures of this project. The
data were collected from only one clinic, limiting the generalization. Additionally, the
sample population was relatively small (n=37), with only 19% of these patients identified as
smokers. The population was also predominantly female (76%), which further limits the
generalizability of the findings to males. Race and ethnicity were not a part of the
demographic data obtained from the chart review. However, the COAT clinic
predominantly serves a Caucasian population, which limits the findings across diverse
ethnic backgrounds. This is a healthcare disparity among ethnicities is recognized in the
literature (Tait & Chibnall, 2014).
Additionally, some patients may not have had full six data points when collecting
pain data. Patients are required to see their PCP every 3-6 months, and therefore data
regarding their GPS and current pain level may have been missed for months which the
patient could not attend the clinic. This missing information may have skewed the results.
Recommendations for Practice
Currently, for each patient, tobacco use status is asked and readiness to quit is
assessed at each COAT appointment. Though not fully investigated in this sample, providers
may recognize the opportunity for brief smoking cessation intervention. It is important that
all 5 A’s are used together to increase effectiveness and likelihood for success (Aveyard, et
al., 2012). In fact, the US Preventative Serve Task Force (2015) gives a grade A
recommendation advising clinicians to screen all patients for tobacco use and asses their
readiness to quit. The 5 A’s offer an opportunity for the provider to evaluate as well as
intervene in tobacco cessation treatment (Kruger et al., 2016; Sui et al., 2016). Providers can
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use motivational interviewing techniques to further explore reasons why patients might be
hesitant to quit. A theoretical framework, such as the HBM, can be used to guide interview
techniques to encourage patients to become self-motivated (Green & Murphy, 2014).
Information regarding smoking cessation should be provided at each visit to all
current and former smokers. Exposure to this information may help patients to recognize the
implications that smoking has on their health, especially in relation to their pain. For
example, a teaching sheet (Figure 3), developed for this project, to inform patients how
smoking affects their pain could be distributed. Distributing this teaching sheet to patients at
a COAT clinic can help expose them to smoking cessation information. This sheet also
provides talking points for the provider which can contribute to the overall plan of care.
The strategy used for assessing smoking cessation in the COAT clinic had patients
indicate interest in smoking cessation on the intake form. Smoking cessation was to be
discussed if the patient desired more information on this topic. Though this was not fully
explored in the project design, one recommendation would be to assess previous quit
attempts on the same intake form. This would streamline the process and conversation
regarding smoking cessation.
Providers must be familiar with available resources to help patients quit tobacco use.
Data has shown group or individual psychological support can help people who want to quit.
This could be actualized by utilizing the 1-800-QUIT- NOW (Patel et al., 2016; Kruger et al.,
2016). Moreover, NRT in combination with behavioral therapy can produce ideal outcomes
regarding tobacco therapy (Fiore et al., 2008). A variety of counseling styles have helped
smokers gain control over their behavior: motivational interviewing, cognitive behavioral
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therapy, and acceptance and commitment therapy (Lindson‐Hawley, 2015, Spears et al.,
2017; Bricker et al., 2017).
Depression and anxiety among chronic pain patients, especially those who smoke,
cannot be ignored. This most prevalent comorbidity is not fully addressed among its
relationship between tobacco and those with chronic pain. Depression and anxiety has been
found to complicate smoking cessation attempts (Zale et al., 2016). Psychiatric services
should be explored and offered to all patients.
Conclusion
Many gaps still exist when addressing smokers with concurrent opioid use. In order to
address these gaps, more research is needed to discover the most effective way for PCPs to
encourage smoking cessation. The goal of chronic pain management is to achieve adequate pain
control in patients with chronic pain. Along with a need to use the 5 A’s to their highest
potential, there is also a need for clinicians to understand the mechanisms between smoking and
chronic pain. When providers collaborate with smokers who experience chronic pain, positive
outcomes can result for all parties involved. By enhancing PCP engagement in tobacco cessation
treatment in patients with chronic pain, their disproportionate tobacco disease burden can be
addressed.
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Table 1. Demographic and clinical characteristics of the sample (n= 37)
Demographic

Mean (SD) or n (%)

Age
Gender

61.9 (9.0)
Male
Female

9 (24.3%)
28 (75.7%)

Smoker
Yes
No
Acceptable pain level (0-10)
Avg Pain at Appointment (1-10)
Global pain score (0-100)
Morphine equivalent
(mg/ME/day)

7 (18.9%)
30 (81.1%)
5.16 (1.95)
6.1 (2.1)
30.5 (19.3)
22.77(13.1)

Table 2. Comparison of pain levels among smokers and non-smokers
Smoker
(n=7)

Pain at Appointment
(1-10)
Global Pain Score
(GPS) (1-100)
Acceptable Pain
Level (1-100)
Morphine Equivalent
(mg/ME/day)

Non-smoker
(n=30)

p

Mean (SD)
7.1 (1.7)

Mean (SD)
5.8 (2.2)

0.14

34.2 (17.4)

21.9 (20.1)

0.71

5.14 (1.5)

5.17 (2.1)

0.9

26.4(12.8)

21.9(13.2)

0.42
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Table 3. Pain Characteristics with Sub-group
Variable

Non-smoker
(n=7)

Smoker
(n=7)

Non-smoker
(n=30)

Average Pain at
Appointment (1-10)

7.0

7.1

5.8

Global Pain Score
(1-100)

27.3

34.2

21.9

Acceptable Pain
Level (1-10)

6

5.14

5.17

Morphine
Equivalent
(MME)

19.6

26.4

21.9

Table 4. Morphine Milligram Equivalent (MME) Conversion table
Medication
mg per day
Morphine
Equivalent
Morphine
1
1
Hydrocodone
1
1
Oxycodone
1
1.5
Tramadol
1
0.1
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Figure 1. Global Pain Scale
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Figure 2. Teaching Sheet

Why Smoking Will Worsen Your Chronic Pain
Short-term relief from nicotine brings long-term problems
Do you look to smoking for relief from a bad back? Or aching joints? Or
abdominal pain?
Cleveland Clinic is a non-profit academic medical center.
Advertising on our site helps support our mission. We do not endorse
non-Cleveland Clinic products or services. Think twice before lighting
up that cigarette. “Nicotine-induced pain relief is short-term. Over time,
smoking may actually worsen your pain,” says pain management
specialist Crawford Barnett, MD.
Smokers are nearly three times as likely to get lower back
pain. Smoking may aggravate abdominal pain and joint pain, as well. In fact, smoking may increase pain
sensitivity in general. About 18% of people in the US are smokers, according to the Centers for Disease
Control and Prevention. Yet smokers make up more than 50 percent of patients who seek pain treatment.

How smoking hurts
The nicotine in tobacco can trick the body into feeling good — at first. It triggers the release of
chemicals, like dopamine, which give off a satisfying, “reward” sensation. It’s what makes smoking so addictive.
But that same tobacco also impairs the delivery of oxygen-rich blood to bones and tissues. Decreasing blood
and nutrient flow can cause degeneration, particularly in discs of the spine, which already have more limited
blood flow. The result can be lower back pain and sometimes osteoporosis.
Physicians also link smoking with fatigue and slower healing, factors that make painful conditions more
prominent. Researchers are exploring even more physiological reasons why smoking makes people
with fibromyalgia, arthritis and other chronic pain hurt more.
“Almost everyone knows smoking can cause cancer, lung disease and cardiovascular disease,” says
Dr. Barnett. “But not everyone realizes that smoking can make your pain worse. ”To make matters worse, when
smokers suffer from debilitating pain, potentially life-changing treatments may not work. “Smokers aren’t the
best candidates for implantable devices such as neurostimulators, which block pain sensation,” says Dr.
Barnett. “Smoking impairs the immune system and increases the risk of infection after surgery.

How to get Started
Dr. Barnett actively counsels patients to quit smoking. “You may look to cigarettes for help coping with pain,
anxiety or stress, but there are healthier ways to do that,” he says. Here’s what he suggests:

•
•
•
•
•
•

Schedule your “quit day.”
Ask your primary care doctor about medication or nicotine replacement products.
Consider additional treatments like acupuncture or hypnosis.
Call 1-800-QUIT-NOW for free help from trained coaches.
Get support from family and friends, and join a support group.
Take a walk whenever you feel the urge to smoke.

You can also start a new exercise program. Exercise activates endorphins, chemicals in the brain that
can help block or lessen pain. “Quitting smoking may be one of the most significant things you can do to both
improve your health and manage your pain,” says Dr. Barnett.
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Figure 3. COAT Clinic Contract
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Figure 4. The 5 A’s of Smoking Cessation
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Figure 5. Average GPS scores
GLOBAL PAIN SCALE (1-100)
Smokers Non-Smokers
(n=7)

(n=30)

June

32

18

July

30.2

19

30

18

36.5

19.5

26

27

24.75

21

August
September
October
November
Average

29.9

21.0

40
35
30
25
20
15
10
5
0
June

July

August
Smokers

September
Non-Smokers

October

November
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Figure 6. Average Pain at time of Appointment (1-10)

Month

Smokers
(n=7)

Non- Smokers
(n=30)

June

6.75

5.5

July

6.4

5.7

6.75

5.6

7.5

5.4

October

6.25

6.1

November

6.75

6.4

6.73

5.79

August
September

Average
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Figure 7. Pain Location
Location

Total

Smoker

Non-Smoker

N=7

N=30

Legs

15

5 (86%)

10 (33%)

Back

13

3 (43%)

10 (33%)

Shoulder

11

2 (29%)

9 (30%)

Feet

10

1 (14%)

9 (30%)

Ankles

5

1 (14%)

4 (13%)

Arms

5

1 (14%)

4 (13%)

Neck

5

1 (14%)

4 (13%)

Hips

4

1 (14%)

3 (10%)

Abdomen

2

1(14%)

1 (3%)

140
120

Frequency (%)

100
80
60
40
20
0
Legs

Back

Shoulder

Feet

Ankles

Location
Smoker

Non-smoker

Arms

Neck

Hips

Abdomen
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Figure 8. Co-morbidities (n=37)

Co-morbidities
80
70

Frequency

60
50
40
30
20
10
0

Diagonsis
Smoker

Non-Smoker

Dx

TOTAL (n=37)

Smoker (n=7)

Non-Smoker (n=30)

HTN
HLD
GERD
COPD
DM
Asthma
Neuropathy
CAD
Dep/Anxiety
GOUT

21 (57%)
20 (54%)
16 (43%)
11 (30%)
21 (57%)
8 (22%)
4 (11%)
7 (19%)
15 (41%)
6 1(6%)

4 (57%)
4 (57%)
2 (29%)
2 (29%)
4 (57%)
2 (29%)
2 (29%)
1 (14%)
5 (71%)
0

17 (57%)
16 (53%)
14 (47%)
9 (30%)
17 (57%)
6 (20%)
2 (7%)
6 (20%)
10 (33%)
6 (20%)
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Figure 9. Diagnoses

Diagnosis

Total

Smoker

Non-Smoker

N= 37

N=7

N=30

Arthritis

11

3 (43%)

8 (27%)

DDD

2

1 (14%)

1 (3%)

Generalized pain

9

4 (57%)

5 (16%)

Arthropathy

3

0

3 (10%)

Neuropathy

3

1 (14%)

2 (7%)

Cervicalgia

2

0

2 (7%)

Diagnosis
60

Fequency (%)

50
40
30
20
10
0
Arthritis

DDD

Generalized pain

Arthropathy

Dignosis
Smoker

Non-Smoker

Neuropathy

Cervicalgia
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Figure 10. CDC Guideline for Prescribing Opioids

